JPMorgan Chase & Co. Has $10.91 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR

JPMorgan Chase & Co. trimmed its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 7.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 192,699 shares of the company’s stock after selling 15,023 shares during the period. JPMorgan Chase & Co. owned about 0.27% of Kymera Therapeutics worth $10,907,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers lifted its position in Kymera Therapeutics by 4.4% in the 3rd quarter. Rhumbline Advisers now owns 74,173 shares of the company’s stock valued at $4,198,000 after acquiring an additional 3,115 shares in the last quarter. Bryce Point Capital LLC purchased a new stake in shares of Kymera Therapeutics in the third quarter worth approximately $335,000. Profund Advisors LLC lifted its holdings in shares of Kymera Therapeutics by 70.0% in the third quarter. Profund Advisors LLC now owns 15,013 shares of the company’s stock valued at $850,000 after purchasing an additional 6,182 shares in the last quarter. Candriam S.C.A. boosted its position in shares of Kymera Therapeutics by 24.4% during the third quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after buying an additional 37,536 shares during the last quarter. Finally, Bessemer Group Inc. grew its holdings in Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently commented on KYMR. Wells Fargo & Company raised their price objective on Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Mizuho raised their price target on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Finally, Citigroup upped their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 81,866 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $90.13, for a total transaction of $7,378,582.58. Following the completion of the transaction, the director owned 675,341 shares in the company, valued at $60,868,484.33. This trade represents a 10.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jeremy G. Chadwick sold 3,919 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $334,290.70. Following the sale, the chief operating officer owned 73,810 shares in the company, valued at $6,295,993. The trade was a 5.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 561,698 shares of company stock valued at $50,388,337. Insiders own 16.01% of the company’s stock.

Kymera Therapeutics Trading Down 3.0%

Shares of NASDAQ KYMR opened at $83.52 on Friday. The stock has a fifty day simple moving average of $78.75 and a two-hundred day simple moving average of $66.52. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The firm has a market cap of $6.82 billion, a price-to-earnings ratio of -22.70 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The firm had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.88) earnings per share. Analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts across Q1–Q4 2026 (small EPS improvements) and reiterated a Buy with a $134 target — this reduces short‑term downside expectations and supports investor interest. HC Wainwright note
• Positive Sentiment: Recent analyst target increases and bullish notes (including UBS coverage and other upgrades) signal renewed conviction in Kymera’s pipeline and cash runway; these reports are a constructive counterbalance to selling. UBS bullish note
• Positive Sentiment: Some outlets raised Kymera price targets (example: a recent note raising a target to $100), which can attract buyers and provide technical support. Price target update
• Neutral Sentiment: Technical/context: KYMR remains above its 200‑day moving average with elevated volatility (beta ~2.2); analyst consensus targets sit well above the current price, which can amplify both rallies and pullbacks. Market data
• Neutral Sentiment: Institutional activity shows modest position changes among several managers; current flows are not large enough to decisively move the stock by themselves. Institutional holdings
• Negative Sentiment: Large insider selling: Director Bruce Booth sold 81,866 shares (~$7.38M at ~ $90), a substantial, visible transaction that can be perceived as profit‑taking and pressuring the stock. Booth Form 4
• Negative Sentiment: Multiple senior executives (CFO, COO and others) disclosed sales across March 2–4, trimming positions by a few percent each—these repeated insider sales amplify short‑term negative sentiment despite company‑level explanations (e.g., diversification or tax/liquidity needs). Insider filings
• Negative Sentiment: Recent quarterly results (Feb. 26) showed an EPS miss and steep revenue decline year‑over‑year, which remains a fundamental drag on the stock until upcoming clinical milestones or revenue inflection points arrive. Earnings report

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.